Annals of Nuclear Medicine

, Volume 27, Issue 10, pp 931–934 | Cite as

Increased 18F-fluoroestradiol uptake in radiation pneumonia

  • Zhongyi Yang
  • Yifei Sun
  • Zhifeng Yao
  • Jing Xue
  • Yongping Zhang
  • Yingjian ZhangEmail author
Case Report


A 54-year-old metastatic breast cancer patient who had undergone chemotherapy and radiotherapy was transferred to our hospital for further treatment. We utilized 18F-fluoroestradiol (FES) to assess the estrogen receptor (ER) status of metastatic lesions. Interestingly, high accumulation of 18F-FES in pneumonia caused by radiation was detected. Hence, this draws oncologists’ attention to the possible false-positive result of 18F-FES, which may lead to inappropriate endocrine therapy.


Breast cancer 18F-FES PET Radiation pneumonitis 


  1. 1.
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29.PubMedCrossRefGoogle Scholar
  2. 2.
    Clark GM, Sledge GW Jr, Osborne CK, McGuire WL. Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol. 1987;5:55–61.PubMedGoogle Scholar
  3. 3.
    Rose C, Thorpe SM, Andersen KW, Pedersen BV, Mouridsen HT, Blichert-Toft M, et al. Beneficial effect of adjuvant tamoxifen therapy in primary breast cancer patients with high oestrogen receptor values. Lancet. 1985;1:16–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Bertelsen CA, Giuliano AE, Kern DH, Mann BD, Roe DJ, Morton DL. Breast cancers: estrogen and progesterone receptor status as a predictor of in vitro chemotherapeutic response. J Surg Res. 1984;37:257–63.PubMedCrossRefGoogle Scholar
  5. 5.
    Amir E, Clemons M, Purdie CA, Miller N, Quinlan P, Geddie W, et al. Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies. Cancer Treat Rev. 2012;38:708–14.PubMedCrossRefGoogle Scholar
  6. 6.
    Simmons C, Miller N, Geddie W, Gianfelice D, Oldfield M, Dranitsaris G, et al. Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? Ann Oncol. 2009;20:1499–504.PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Sundararajan L, Linden HM, Link JM, Krohn KA, Mankoff DA. 18F-Fluoroestradiol. Semin Nucl Med. 2007;37:470–6.PubMedCrossRefGoogle Scholar
  8. 8.
    McGuire AH, Dehdashti F, Siegel BA, Lyss AP, Brodack JW, Mathias CJ, et al. Positron tomographic assessment of 16 alpha-[18F] fluoro-17 beta-estradiol uptake in metastatic breast carcinoma. J Nucl Med. 1991;32:1526–31.PubMedGoogle Scholar
  9. 9.
    Mintun MA, Welch MJ, Siegel BA, Mathias CJ, Brodack JW, McGuire AH, et al. Breast cancer: PET imaging of estrogen receptors. Radiology. 1988;169:45–8.PubMedGoogle Scholar
  10. 10.
    Peterson LM, Mankoff DA, Lawton T, Yagle K, Schubert EK, Stekhova S, et al. Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol. J Nucl Med. 2008;49:367–74.PubMedCrossRefGoogle Scholar
  11. 11.
    van Kruchten M, Glaudemans AW, de Vries EF, Beets-Tan RG, Schröder CP, Dierckx RA, et al. PET imaging of estrogen receptors as a diagnostic tool for breast cancer patients presenting with a clinical dilemma. J Nucl Med. 2012;53:182–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Payne SJ, Bowen RL, Jones JL, Wells CA. Predictive markers in breast cancer—the present. Histopathology. 2008;52:82–90.PubMedCrossRefGoogle Scholar
  13. 13.
    Sharangpani GM, Joshi AS, Porter K, Deshpande AS, Keyhani S, Naik GA, et al. Semi-automated imaging system to quantitate estrogen and progesterone receptor immunoreactivity in human breast cancer. J Microsc. 2007;226:244–55.PubMedCrossRefGoogle Scholar
  14. 14.
    Pusztai L, Mazouni C, Anderson K, Wu Y, Symmans WF. Molecular classification of breast cancer: limitations and potential. Oncologist. 2006;11:868–77.PubMedCrossRefGoogle Scholar
  15. 15.
    Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28:2784–95.PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Podoloff DA, Ball DW, Ben-Josef E, Benson AB 3rd, Cohen SJ, Coleman RE, et al. NCCN task force: clinical utility of PET in a variety of tumor types. J Natl Compr Canc Netw. 2009;7:S1–26.PubMedGoogle Scholar
  17. 17.
    Kovats S. Estrogen receptors regulate an inflammatory pathway of dendritic cell differentiation: mechanisms and implications for immunity. Horm Behav. 2012;62:254–62.PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Bonds RS, Midoro-Horiuti T. Estrogen effects in allergy and asthma. Curr Opin Allergy Clin Immunol. 2013;13:92–9.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© The Japanese Society of Nuclear Medicine 2013

Authors and Affiliations

  • Zhongyi Yang
    • 1
    • 2
  • Yifei Sun
    • 1
    • 2
  • Zhifeng Yao
    • 1
    • 2
  • Jing Xue
    • 1
    • 2
  • Yongping Zhang
    • 1
    • 2
  • Yingjian Zhang
    • 1
    • 2
    Email author
  1. 1.Department of Nuclear MedicineFudan University Shanghai Cancer CenterShanghaiChina
  2. 2.Department of Oncology, Shanghai Medical CollegeFudan UniversityShanghaiChina

Personalised recommendations